NRG-LU005

NCT03811002 📎

Regimen

Experimental
Concurrent chemoradiation + atezolizumab 1200 mg q3w concurrent and adjuvant (up to 17 cycles)
Control
Concurrent chemoradiation alone (platinum/etoposide + 66 Gy QD or 45 Gy BID)

Population

Limited-stage SCLC, stage Tx-IV, N0-3, M0, ECOG PS 0-2, after 1 induction chemo cycle

Key finding

mOS 31.1 mo (CRT+atezo) vs 36.1 mo (CRT alone); HR 1.03 (95% CI 0.80-1.32); mPFS 12.1 vs 11.4 mo; no OS benefit from adding atezolizumab

Source: PMID 41529214

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.50)⚠️ OCR source